Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.7355 EUR 2.65% Market Closed
Market Cap: 498.9m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Pharming Group NV
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharming Group NV
Research & Development Peer Comparison

Comparables:
PRQR
QURE
ARGX
MRUS
LVTX

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Pharming Group NV
AEX:PHARM
Research & Development
-$72.5m
CAGR 3-Years
-1%
CAGR 5-Years
-11%
CAGR 10-Years
-21%
ProQR Therapeutics NV
NASDAQ:PRQR
Research & Development
-€29.5m
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Research & Development
-$150.3m
CAGR 3-Years
-4%
CAGR 5-Years
-12%
CAGR 10-Years
-15%
argenx SE
XBRU:ARGX
Research & Development
-$1B
CAGR 3-Years
-29%
CAGR 5-Years
-42%
CAGR 10-Years
-71%
Merus NV
NASDAQ:MRUS
Research & Development
-$191.6m
CAGR 3-Years
-27%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Research & Development
-$33.8m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Pharming Group NV's Research & Development?
Research & Development
-72.5m USD

Based on the financial report for Jun 30, 2024, Pharming Group NV's Research & Development amounts to -72.5m USD.

What is Pharming Group NV's Research & Development growth rate?
Research & Development CAGR 10Y
-21%

Over the last year, the Research & Development growth was -21%. The average annual Research & Development growth rates for Pharming Group NV have been -1% over the past three years , -11% over the past five years , and -21% over the past ten years .

Back to Top